The USFDA has revised the authorizations for two monoclonal antibody treatments bamlanivimab and etesevimab sold by Eli Lilly and Regeneron’s casirivimab and imdevimab – to limit their use to only when the patient is likely to have been infected with or exposed to a variant that is susceptible to these treatments.
“Because data show these treatments are highly unlikely to be active against the omicron variant, which is circulating at a very high frequency throughout the United States, t ..
According to the data of the US Centers for Disease Control and Prevention, the omicron variant of SARS-CoV-2 is estimated to account for more than 99% of cases in the US as of January 15.
The USFDA revision of approval was based on the National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel, an independent panel of national experts, recently recommended against the use of the two monoclonal antibodies because of markedly reduced activity against the omicron variant and ..
